Many advances have been made in the past decade in the treatment of schizophrenia. There have also been advances in the understanding the etiopathophysiology of schizophrenia, with much work studying neurochemical, neuroanatomical, genetic, and postmortem domains. New research has focused on early detection of schizophrenia, cognitive impairments, and improving long-term outcomes for patients who suffer from this devastating illness.1–3 Progress has been particularly due to a new class of medications the second-generation antipsychotics (SGAs), which have become available in the last 7 years. However, despite these research efforts, there is still a great deal that we do not know about schizophrenia. Most studies and clinical trials involve participation of adults (18–65 years) who do not have substance-abuse problems and are free from other concomitant disease states, medications, and other symptom domains. Therefore, although it is a growing area, clinical research and understanding of optimal treatment for special patient populations has received little recognition.

This paper will review the current state of treatment for schizophrenic patients who are considered to be in special patient populations; these include children and adolescents, the elderly, substance abusers, and patients who are considered to be resistant to traditional medications.

Epidemiological data show that 10% to 30% of patients with schizophrenia develop their first psychotic symptoms prior to their 18th birthday.4–6 Onset before the age of 18, but beyond puberty is sometimes classified as early-onset schizophrenia or intermediate-onset schizophrenia and those presenting with symptoms before the ages of 12 to 14 years (prepubertal) are labeled as patients with very-early-onset schizophrenia or as having childhood-onset schizophrenia.7 More male adolescents (2:1) may develop very-early-onset schizophrenia than females; however, the overall prevalence at this young age is very low: 1/10 000.8

The diagnosis of schizophrenia in children and adolescents is often difficult to make and should be differentiated from pervasive developmental disorders, attention-deficit/hyperactivity disorder, and language or communication disorders. If a child has prominent hallucinations or delusions, however, the diagnosis of schizophrenia should be considered. Auditory hallucinations are common and occur in approximately 80% of children...
Children and adolescents with schizophrenia. Command hallucinations are the most frequently occurring type of hallucination. The content and context of delusions in children and adolescents are varied by age with younger children tending to be less complex and less “fixed.” Some 54% to 90% of patients developing schizophrenia before age 18 will have premorbid abnormalities such as withdrawal, odd traits, and isolation.

Treatment for psychotic children and adolescents ideally involves an intensive and comprehensive program. A highly structured environment with special education and psychoeducation is recommended. Day treatment, hospitalization, or long-term residential treatment may be necessary. Pharmacologic treatment is indicated if positive psychotic symptoms cause significant impairments or interfere with other interventions. Traditional antipsychotics have modest efficacy in children and adolescents at doses between 10 to 200 chlorpromazine equivalents. Few studies with the conventional antipsychotics have been published in this population. Three controlled clinical trials to examine the safety and efficacy in children and adolescents with schizophrenia have been published. The low-potency agents should be particularly avoided in this population because of sedation and anticholinergic side effects, which may lead to cognitive dulling and interference with schoolwork. Children and adolescents are also more vulnerable to extrapyramidal side effects (EPS), namely dystonias, than adults. Due to concerns with EPS and tardive dyskinesia (TD) in this group, many children and adolescents are initiated on SGAs and traditional agents are not generally used as first-line therapy.

Several open trials and case series have reported the use of clozapine in children and adolescents for the treatment of schizophrenia. Kumra et al compared clozapine with haloperidol in a double-blind fashion in patients aged 6 to 18 with a poor response to antipsychotics. The dosage of clozapine ranged from 25 to 525 mg/day with a mean dosage of 176 mg/day. Clozapine was found to be superior to haloperidol and particularly beneficial for negative symptoms. Although most young patients have improvement during clozapine therapy, side effects in this population may be more pronounced and frequent than in adults. The most prominent symptoms seen are somnolence, hyposialivation, and weight gain. Children and adolescents tend on average to gain more weight than reported in the adult literature. Mean weight gains are up to 7 kg in 6 weeks. Seizures have been reported and may be more frequent than the 3% to 6% prevalence in adults. The risk for agranulocytosis appears to be similar to adults. Children and adolescents who have been found to be resistant to at least two trials of antipsychotics including another SGA may benefit from a trial of clozapine, but it should be used only as a last resort therapy. Young patients should be treated initially with lower doses than adult patients and be titrated at a slower rate. Side effects should be monitored closely during initiation and throughout maintenance therapy. Enuresis may occur with clozapine and often occurs at higher rates in children and adolescents.

The number of published reports of the use of risperidone in children and adolescents has been growing rapidly in the past couple of years. Several reports of risperidone use for patients with pervasive developmental disorders have been published. Additionally, many recent publications cite risperidone use for conduct disorder, aggression, bipolar disorder, developmental disabilities, and obsessive compulsive disorder. Armenteros et al published a short-term, open-label study for 10 adolescents with a diagnosis of schizophrenia. Although responses similar to the adult population were seen, the mean dosage used was very high, 6.6 mg/day (range 4–10 mg/day), and well beyond what is currently used clinically for adolescents and adults alike. All other reports for patients with schizophrenia, to our knowledge, have been case reports and chart reviews. Dosing of risperidone in current reports in diseases other than schizophrenia generally use initial dosages of 0.25 to 0.5 mg/day and stabilize patients on dosages of 1.5 to 3 mg/day. Risperidone is known to cause EPS in adults as dosing increases above 6 mg/day.

Because young patients are more susceptible to these effects and optimal efficacy is known to occur at lower
doses,7 the dosage of risperidone for the treatment of schizophrenia in children and adolescents should be in the range of 0.5 to 4 mg/day. Children and adolescents more often report tiredness and sedation with risperidone treatment than adults.32 Also unlike the adult population, there have been a few reports of stereotypies and elevations in liver enzymes occurring.33,34 Other side effects, apart from weight gain, are usually mild and similar to the adult population. Weight gain has been fairly well documented in the adolescent population and appears more pronounced than in adults. Kelly et al35 reported mean gains of 8.7 kg over 6 months of treatment with risperidone—significantly more than that of traditional antipsychotics (3.0 kg) or no antipsychotic (-1.0 kg) during the same period. Martin and colleagues36 reported clinically significant weight gains in 78% of children and adolescents treated with risperidone compared with 24% in a comparison group; the average weight gain was 1.2 kg/month. Risperidone is known to cause the greatest prolactin elevations of the SGAs dependent on both dose and dopamine D2 receptor occupancy.41 At higher doses, there have been reports of menstrual irregularities occurring in young patients42 and galactorrhea has occurred in both sexes during clinical treatment. When side effects occur, lowering the dose of risperidone has often been found to be effective. Olanzapine, like risperidone, has been widely studied in adolescents, and appears more pronounced than in adults. Kelly et al35 reported mean gains of 8.7 kg over 6 months of treatment with risperidone—significantly more than that of traditional antipsychotics (3.0 kg) or no antipsychotic (-1.0 kg) during the same period. Martin and colleagues36 reported clinically significant weight gains in 78% of children and adolescents treated with risperidone compared with 24% in a comparison group; the average weight gain was 1.2 kg/month. Risperidone is known to cause the greatest prolactin elevations of the SGAs dependent on both dose and dopamine D2 receptor occupancy.41 At higher doses, there have been reports of menstrual irregularities occurring in young patients42 and galactorrhea has occurred in both sexes during clinical treatment. When side effects occur, lowering the dose of risperidone has often been found to be effective. Olanzapine, like risperidone, has been widely studied in adult populations,37 but data for adolescents with schizophrenia are scarce. The only study in the adolescent schizophrenic population43 reported an open trial of olanzapine in patients aged 10 to 17 years. The mean dosage was 17.5 mg/day and the side effects reported included weight gain, increased appetite, anticholinergic side effects, and sedation. Difficulty concentrating, sustained tachycardia, headache, nausea and vomiting, and transient liver elevations were also reported in this study. Although not comparatively studied, olanzapine treatment in young populations appears to cause greater weight gains than risperidone: Potenza44 reported over 8 kg in only 12 weeks of treatment. Unlike the transient rise and fall in the adult population, a recent report found sustained prolactin elevation in 70% of children and adolescents treated with olanzapine, but little has been published regarding clinical side effects of this phenomenon.45 The mean dosages being used in the adolescent population are between 5 and 20 mg/day. It is not yet clear what is the ideal dose range for olanzapine in this group.

There is one open-label trial of quetiapine in adolescents with psychotic disorders reporting an improvement from baseline in both positive and negative symptoms. The most commonly occurring side effects were postural tachycardia and insomnia.47 Currently, little is known about the most appropriate dosing for this population. Dosages of 200 to 800 mg/day are being reported. More research is needed to ascertain the safety and dosing of quetiapine, especially in the young population.

SGAs show great promise in the treatment of psychotic symptoms in patients who are under the age of 18 for symptom improvement and tolerability. Dosing for clozapine and risperidone in particular should be initiated and maintained at doses lower than the adult population. All of the SGAs appear to cause weight gain in the adolescent population, which is the biggest drawback to their routine use; this appears to occur most often with olanzapine and clozapine. Informed consent, addressing the rationale for treatment and potential risks and benefits of therapy, should be obtained from the parents/guardians prior to treatment with any antipsychotic medication and assent should be obtained from the children. Standardized clinician rating, such as the Positive and Negative Syndrome Scales (PANSSs) derived from the Children’s Psychiatric Rating Scale, is sensitive to antipsychotic improvements in children and adolescents, and can be helpful in assessing the effects of antipsychotic therapy.

Treatment of psychosis in the elderly

Schizophrenic symptoms in late life (>65 years) are generally a result of a chronic illness carrying over from younger life; however, few patients may develop psychotic symptoms de novo.48 Data from the Epidemiological Catchment Area Study49 showed 6-month prevalence rates of schizophrenia in the elderly to be 0.2% to 0.9%. Other illnesses displaying psychotic symptoms are extremely high in this population: 0.1% to 1.6% for psychotic depression and 16.8% to 23% for organic psychosis.50 Additionally, approximately one third of patients with Alzheimer’s disease (AD), Parkinson’s disease (PD), and vascular dementia experience psychotic symptoms and the majority of data for antipsychotic use come from treating these disease states.51-53 For institutionalized patients, antipsychotics are the most widely prescribed psychotropic drugs.54 Because of the
Antipsychotics can be safe and effective for the treatment of psychosis if used at lower doses than commonly used in younger adults. Older adults are particularly vulnerable to the side effects of conventional antipsychotics. PD symptoms reportedly occur in over 50% of all elderly patients receiving these agents and the cumulative annual incidence of TD in middle-aged and elderly patients is over 25%. The likelihood of reversing this potentially debilitating condition diminishes with age. Other adverse effects of these agents that are often intolerable in the older population include orthostatic hypotension and anticholinergic effects. Orthostasis is estimated to occur in 5% to 30% of geriatric patients and is a major contributing factor to the occurrence of falls. The elderly are also more prone to the consequences of falls, such as bone fractures, injuries, and dependency. Low-potency antipsychotics and clozapine are more likely to cause significant drops in orthostatic blood pressure. Anticholinergic effects in the elderly may cause side effects, such as constipation, dry mouth, urinary retention, and cognitive impairment. The elderly are especially sensitive to these effects and the use of laxatives or stool softeners is already problematic for elderly patients with schizophrenia.54 Clozapine therapy should be initiated at 12.5 to 25 mg/day given in two divided doses, titrating by increments of 12.5 mg over 5 to 7 days. Controlled studies examining the efficacy of clozapine in the elderly specifically for patients with schizophrenia are rare. Howanitz and colleagues studied clozapine (maximum 300 mg/day) compared with chlorpromazine (maximum 600 mg/day) in a 12-week, double-blind fashion in patients with chronic schizophrenia. Patients on clozapine tended to do better than the chlorpromazine group, although this did not reach significance, probably due to the sample size. Tachycardia and weight gain were problematic for clozapine-treated patients, while those treated with chlorpromazine were highly sedated. Clozapine should be used as a last resort in geriatric patients with schizophrenia and at least one trial of an SGA should be made first.

Risperidone has been shown to be effective in the elderly with schizophrenia, schizoaffective disorder, major depression with psychotic features, bipolar disorder, and delusional disorder. A dosage range of 0.5 to 3 mg/day is the optimal range for the treatment of psychotic symptoms in the elderly. Initially, patients should receive 0.25 to 0.5 mg taken once daily with titration in increments not greater than 0.5 mg/24 hours. A few recent, large, open-label studies with risperidone for geriatric patients with schizophrenia have been published. A 12-month, multicenter trial included 180 patients with a mean age of 72 years and found that 54% of patients had a 20% reduction in PANSS scores at a mean dosage of 3.7 mg/day. Likewise, Madhusoodanan et al found significant symptom improvements over 12 weeks in 103 elderly patients with schizophrenia or schizoaffective disorder. In these and other open studies, risperidone is well tolerated with the most common side effects being orthostatic hypotension and sedation. The rates of EPS are low if risperidone is used at low doses. Most elderly patients in the studies had decreased use of anticholinergic medications and improvements in EPS from baseline. The risk of TD with risperidone treatment is significantly less than conventional antipsychotic treatment in the geriatric population (4% versus 25%).

Very little data exist for the treatment of schizophrenia in the elderly with olanzapine. Very few patients over 65 were included in premarketing trials and no controlled trials are yet available for this population. An open-label study of olanzapine 5 to 20 mg/day found
significant improvements in positive and negative symptoms in schizophrenic patients aged 60 to 85 years. Side effects were minimal and generally well tolerated. Another open trial giving olanzapine as an adjunct (mean dosage 8.4 mg/day) to current therapy found significant improvements in EPS; however, no significant improvements were noted on the Brief Psychiatric Rating Scale (BPRS). Most other data available for olanzapine in the elderly relate to its use in AD and PD. While low-dose olanzapine appears well tolerated and effective for AD patients at dosages of 5 to 10 mg/day, patients with PD suffer from unacceptable aggravation of parkinsonism even at low doses. The starting dosage of olanzapine should be 2.5 to 10 mg/day and increased by 5 mg no more frequently than every 7 days to a target range of 5 to 15 mg/day in patients with schizophrenia and lower dosages for those with AD.

There are several reports of the use of quetiapine in the elderly for the treatment of psychosis with PD. On the basis of both its receptor-binding affinity and its low liability for EPS clinically, it is a good first-line selection for this disorder and may be an option for patients who have been taking clozapine. Dosages for psychosis associated with PD are generally 12.5 to 300 mg/day. No controlled studies are currently available for quetiapine use in patients with the diagnosis of schizophrenia only. Two open-label studies and one case series have been reported consisting of patients with a psychotic disorder associated with a mixture of diagnoses and found significant improvements in psychotic symptoms. Somnolence, dizziness, and postural hypotension were the most frequently occurring adverse effects, but the majority of cases were considered mild to moderate. Weight gain and EPS occur at low rates with quetiapine use. Dosing for geriatric patients with schizophrenia is not well studied. Dosages used in reports averaged 100 to 150 mg/day, but these dosages were studied in a population with mixed diagnoses. SGAs appear to be beneficial in the geriatric population at much lower doses than are used in adults. Because geriatric patients are often on many medications and suffer from numerous disease states, vigilance is needed when prescribing the newer medications. Clozapine and olanzapine are metabolized by the cytochrome P-450 isoenzyme 1A2, which may be inhibited by several medications, therefore leading to higher blood levels. This may be compounded in geriatric patients by their already compromised metabolism and clearance of medications. Additionally, women may potentially be more prone to side effects, since the blood levels of both these medications are higher in women than men.

This population is particularly prone to falls and anticholinergic side effects, such as constipation, confusion, blurry vision, urinary retention, and dry mouth. All of these antipsychotics block α-receptors leading to some orthostasis. Patients should be advised to stand or sit up slowly, especially upon medication initiation. Using lower doses and selecting the least anticholinergic of the medications helps prevent these other adverse effects. Very little data comparing these medications with conventional agents or among SGAs are available. Quetiapine should be used as a first-line agent for psychosis associated with PD.

Treatment of schizophrenia in patients with substance abuse

The prevalence of substance abuse among persons with schizophrenia is significantly higher than in the general population. Conservative estimates are that one third to as many as one half of people with schizophrenia abuse alcohol and illicit drugs. Dually diagnosed patients are more likely to be noncompliant with treatment and medications particularly because of side effects. These people also have a poorer response rate to traditional antipsychotics and have higher rates of rehospitalization. For patients discharged on traditional antipsychotics, substance abuse is one of the most significant reasons for readmission. EPS may occur more frequently in patients who are substance abusing, and the use of illicit drugs and alcohol is a risk factor for the development of TD.

There is evidence that substance-abusing patients respond differently to conventional antipsychotics than non–substance-abusing patients. A few studies have reported that substance-abusing patients receiving fixed doses of haloperidol and perphenazine had a poorer response and more readmissions than non–substance-abusing patients. This is very likely due to the fact that the substance-abusers suffer increased rates of parkinsonian side effects from conventional antipsychotics and are less compliant. Substance-abusing patients usually have more floridly psychotic symptoms and higher relapse rates. Despite the fact that substance-abusing patients do poorly with traditional
antipsychotic treatment, this group has been found to have better premorbid functioning and less functional impairment than non–substance-abusing schizophrenic patients. It is possible that, while this group is difficult to treat, they may paradoxically represent a subgroup with a better potential for recovery and perhaps a better opportunity for successful reintegration into community living.

SGAs may offer effective clinical treatment for schizophrenic patients with comorbid substance abuse. These medications are associated with better compliance rates than traditional agents as well as lower rates of rehospitalization. Additionally, they have very little liability for causing TD. Unlike what has been observed during conventional antipsychotic treatment, it has been reported that treatment with clozapine is associated with similar response rates between patients with and without a history of substance abuse. There is a rapidly growing body of literature indicating that clozapine treatment may actually be associated with a reduction in the use of illicit drugs and alcohol, but no double-blind, controlled studies are available. Furthermore, clozapine has been given to cocaine addicts prior to an intranasal dose of cocaine and was noted to significantly diminish the effects of the cocaine as well as lessen the paranoia and nervousness associated with its use.

There are no controlled data available for dually diagnosed schizophrenic patients treated with risperidone. There is no reason to believe, however, that this agent would not be a good selection in patients with schizophrenia and a current or past history of substance abuse. It possesses the favorable benefits of the SGAs particularly the lower recidivism and the risk for TD, which may be of benefit in these dually diagnosed patients. There are several case reports that risperidone is effective in substance abuse, such as amphetamine-induced psychosis, inhalant abuse, cocaine craving, metamphetamine-associated obsessive-compulsive disorder, and alcohol hallucinosis. However, only one double-blind trial exists examining risperidone use for cannabis-induced psychotic disorder. These patients did not differ in outcomes by drug group; however, those treated with olanzapine had fewer EPS during treatment. Very little additional data are available for dually diagnosed patients treated with olanzapine. Likewise, few data are available for comorbid substance abuse and the treatment of schizophrenia with quetiapine.

Although the clinical reality of substance abuse among patients with schizophrenia is widely known, the relationship of these diagnoses and optimal treatments is neither well understood nor studied. Paradoxically, dually diagnosed patients have a better potential for recovery, but may have more symptomatology and side effects. From the data available, this population of patients with schizophrenia will likely benefit more from an SGA than a conventional treatment, and should be expected to respond in the same way as those who are not abusing. Clozapine is the only antipsychotic among the SGAs that appears to provide additional benefits to this group by actually reducing cravings for and use of both illicit drugs and alcohol, but this needs to be studied in a controlled fashion.

**Treatment-resistant schizophrenia**

One fifth to one third of all cases of schizophrenia are resistant to drug treatment. This finding has been consistent over time. These patients are highly symptomatic and require extensive periods of hospital care. There was a great deal of excitement following the demonstration of clozapine’s efficacy in inpatients with treatment-resistant schizophrenia. However, clozapine treatment carries with it a significant morbidity from serious side effects, the need for continual weekly blood monitoring, and a high cost. Many clinicians and patients hoped that other new antipsychotics would share clozapine’s effectiveness without its most serious side effects, but no other antipsychotic in this group has clozapine’s efficacy.

Commonly, treatment resistance has been considered to be roughly equivalent to chronic or frequent hospitalization. This, by itself, is not an adequate definition. Patients should also have current and persistent
positive symptoms of psychosis and at least moderate overall severity of illness in order for nonresponsive-ness to apply.\textsuperscript{138} as chronic hospitalization can occur despite low levels of symptoms.\textsuperscript{138} Many people with schizophrenia who have been chronically hospitalized may not be truly resistant to drug treatment. Inadequate psychosocial programming, poor compliance with prescribed drug therapy, or a history of committing violence are all risk factors for chronic hospitalization.\textsuperscript{138} Therefore, an optimized medication and treatment trial should be employed before a patient's illness is considered non-responsive. In addition, the effects of drug noncompliance and EPS can both mimic true treatment resistance.\textsuperscript{137,138} At least a 1- to 2-year course of persistent symptoms should also be considered as one of the criteria for treatment resistance in schizophrenia, because of the waxing and waning course of this illness.

The most widely accepted current criteria for treatment resistance in schizophrenia were first used by Kane et al.\textsuperscript{127} These criteria, modified for clinical use, are as follows:

- Persistent positive psychotic symptoms (item score ≥ 4) on at least two of four positive symptom items on the BPRS: hallucinatory behavior, suspiciousness, unusual thought content, or conceptual disorganization.

- Current presence of at least a moderately severe illness as rated by the total BPRS (score ≥45 on the 18-item scale) and a score of ≥4 on the Clinical Global Impression (CGI) scale.

- Persistence of illness: no period of good social and/or occupational functioning within the last 5 years.

- Drug-refractory condition defined as at least two periods of treatment in the preceding 5 years with appropriate doses of conventional or SGAs, each without clinically significant symptom relief.

The rates for two retrospective drug trial failures have been found to be similar to the rates for three when screening for treatment resistance; this fact is now widely accepted.\textsuperscript{138} People not responsive to two adequate antipsychotic trials (one retrospective and one prospective) have less than a 7% chance of responding to another trial.\textsuperscript{138} The Food and Drug Administration (FDA) guidelines for clozapine, as reflected in the product labeling for clozapine,\textsuperscript{136} also states that people should fail to respond to two separate trials of antipsychotics, before being treated with clozapine.

It is generally recognized that a 4- to 6-week period (rather than strictly a 6-week one) is adequate for a treatment trial of an antipsychotic.\textsuperscript{140} Dosages of >400 mg/day of chlorpromazine have been shown to be adequate to block 80% to 90% of dopamine receptors (thought to be the target of this drug action).\textsuperscript{142} Higher doses produce no direct therapeutic benefit, even in patients not responsive to therapy, and do not have greater efficacy in acute treatment than lower doses.\textsuperscript{143,145} Therefore, two 4- to 6-week trials of 400 to 600 mg/day chlorpromazine or a chlorpromazine equivalent are now accepted as a standard for an adequate trial.\textsuperscript{138,146}

Until the arrival of standardized criteria for defining treatment resistance, research into the neurobiological nature of the problem had been scant.\textsuperscript{147} Recently, however, with the use of more objective criteria, some consistent findings have been seen. There is a relative paucity of data in this area and more research needs to be done. People with treatment-resistant schizophrenia appear to have increased cortical atrophy on magnetic resonance imaging (MRI) compared with those with responsive illness.\textsuperscript{138,148} This was particularly true if they had predominant negative symptoms.\textsuperscript{150} Lack of response to early treatment is also predictive of nonresponse.\textsuperscript{148} The most intriguing finding about predicting which new drugs may be effective in treatment-resistant schizophrenia has been the fact that these people appear to have lower catecholamine levels in the cerebrospinal fluid (CSF).\textsuperscript{149} Clozapine response has been associated with low ratios of CSF homovanillic acid to 5-hydroxyindoleacetic acid.\textsuperscript{150} These findings suggest that drugs with low dopamine antagonism and high serotonergic antagonism may be particularly useful in treatment-resistant schizophrenia. Also, cognitive disorganization has recently been reported to be higher in patients with treatment-resistance than in those who are partial or full responders.\textsuperscript{153}

Historically, drug therapy for treatment-resistant schizophrenia centered on the use of either different dose strategies of conventional antipsychotics or adjunct agents, such as lithium, β-blocking drugs, anticonvulsants, and benzodiazepines. Since the arrival of clozapine, attention in the field has shifted to a greater focus on the use of new antipsychotics for treatment resistance in schizophrenia. This interest occurred because of the demonstration of the superior efficacy of clozapine and the fact that new antipsychotics have been shown to have either significantly fewer side effects or improved efficacy compared with a conventional antipsychotic in order to be marketed in the USA. Conventional antipsychotic medications have worked poorly in this population and in
controlled trials in people with drug-resistant symptoms, fewer than 5% responded after having their drug therapy changed from one conventional antipsychotic to another.127,154 SGAs should be the first consideration after the failure of conventional drug therapy. These drugs are also effective as first-line therapy (with the exception of clozapine, because of its serious side effects).

Clozapine remains the only drug with proven efficacy in rigorously defined treatment-resistant schizophrenia and approximately 30% to 50% of treatment-refractory patients will respond to this medication.155 However, fewer than 8% of new antipsychotic prescriptions are written for this medication in the USA. This phenomenon of relative underusage of clozapine probably relates to the costs and complexities of clozapine therapy. These arise from the need for long-term hematologic monitoring for agranulocytosis and persistent serious side effects present with clozapine, such as weight gain, sialorrhea, and sedation. The optimal dose strategy for clozapine is a slow dose escalation. Patients should be evaluated for response at dosage plateaus of 200 to 400 mg/day and 500 to 600 mg/day. Only patients with few side effects to clozapine should be titrated to dosages higher than 600 mg/day. Patients should not be titrated to a higher dose of clozapine if myoclonus is present, as this side effect may precede the development of seizures.156

Risperidone has been found to be more effective than conventional antipsychotics for positive and affective symptoms in patients with acute schizophrenia.16 For patients with treatment resistance, the most rigorously defined double-blind trial found a 24% response rate to risperidone, compared with 11% for haloperidol after 4 weeks.157 A few other double-blind studies have compared risperidone with clozapine and found similar response rates between drugs, but concerns about the parallel between risperidone and clozapine, because of its serious side effects.

A few studies have reported favorable response rates to olanzapine in patients with treatment-resistant schizophrenia of 36% to 47%.141-165 However, there is some controversy regarding these findings. These studies included patients who were considered treatment-resistant and those who were intolerant to clozapine. A study by Conley et al166 in well-characterized, treatment-resistant patients with schizophrenia found only a 7% response rate to olanzapine in this population and 41% of these treatment failures went on to respond to clozapine.165 Likewise, an open trial of olanzapine in treatment-refractory patients reported no significant improvements in patients treated for at least 6 weeks on 10 to 20 mg/day.166 Therefore, olanzapine does not have a pattern of response similar to clozapine in a well-characterized sample, but may offer a slightly better rate of response than traditional antipsychotic therapy. Very little data on quetiapine use in treatment-resistant schizophrenia are available. A few brief reports suggest it may be beneficial to chronic or partial conventional responders167-169; however, no controlled trials for treatment resistance have been published.

If patients remain refractory to treatment after trials of SGAs, alternative therapies should be considered. Most of the data for adjunctive treatment are, however, limited and come from case reports and open trials. Adjunct lithium therapy has been seen to be beneficial in some patients with treatment-resistant schizophrenia; however, these patients were often not defined by the rigorous criteria of later studies.123,129,170 The published trials of adjunct lithium that are positive were conducted with small numbers of patients, and the criteria for defining treatment resistance were often not clear, or were overinclusive.171 More recent reports have found no benefits with adjunct lithium therapy and fluphenazine decanoate.172 A recent report of 5 male patients with schizophrenia treated with olanzapine showed significant improvements with the addition of lithium.173 Lithium should be used with caution in combination with conventional antipsychotics or clozapine because of the recognized dangers of delirium, encephalopathy, and neurotoxicity that have been reported with these combinations.118,174,175 Carbamazepine and valproic acid have been observed to be effective in bipolar disorder176,177 and are often considered as an adjunctive therapy in patients with schizophrenia. However, these trials included relatively few subjects. Positive effects seen with carbamazepine and valproate have been modest and usually involved non-specific improvement in areas such as behavior and social adjustment. Carbamazepine should be used with caution because it is a potent enzyme inducer and can also reduce the blood level of haloperidol by as much as 50%.178 Carbamazepine should not be used in combination with
There are few data for newer anticonvulsants; however, a few positive results were seen with lamotrigine adjunctive treatment with clozapine.\textsuperscript{179} Electroconvulsive therapy (ECT) for treatment-refractory schizophrenia has had favorable response in short-term trials when added to antipsychotic medications. However, in spite of more than five decades of widespread clinical use, the administration of ECT lacks a strong research base. A recent literature review\textsuperscript{180} reports that about 20% patients will have improvement with this combination. Several recent case reports have noted improvements and controlled trials are currently underway.\textsuperscript{181-185} The combined treatment with clozapine appears to be well tolerated and associated with few adverse effects. However, the issues of persistence of effect and long-term maintenance of these patients have not yet been adequately addressed.

Combined antipsychotic therapy has recently drawn some attention, as many patients (approximately 15%) currently are treated in this way.\textsuperscript{186} While this use is growing, little research is available to support this treatment approach.\textsuperscript{187} The most consistent data thus far come from a few case reports suggesting added improvements to clozapine treatment by the addition of risperidone.\textsuperscript{188-192} Two cases of olanzapine addition to clozapine have reported favorable results.\textsuperscript{193} There is report of the combined use of risperidone and olanzapine with success.\textsuperscript{194} Other reports include the addition of pimozide, sulpiride, and loxapine to treatment-resistant patients treated with clozapine.\textsuperscript{195-198} The addition of a antipsychotic with D\textsubscript{2}-blocking abilities may enhance clozapine treatment in partial responders, but large-scale studies are needed. Other adjunctive therapies reported are associated with very little data or have not been clearly found to be useful for treating symptoms of schizophrenia. There have been some reports of benzodiazepines,\textsuperscript{199} but no clear benefits in symptoms other than associated anxiety have been found.\textsuperscript{128,131,200,201} There are historical studies suggesting that β-blockers may be useful in refractory schizophrenia.\textsuperscript{135} However, there are no available controlled studies using current diagnostic criteria. There is very limited evidence that long-term therapy with β-blockers is beneficial.\textsuperscript{202}

A defined approach to patients with treatment-resistant schizophrenia is critical. As the antipsychotics being introduced today may have different mechanisms of action from conventional antipsychotics and from each other, clinicians will need to explore the possibility of response with each of these new agents in turn with their patients who suffer from persistently refractory symptoms. To date, clozapine is the only mediation with demonstrated efficacy in treatment resistance. The differential efficacy of new drugs in treatment-resistant schizophrenia will only be clear when well-designed, double-blind studies using rigorous entry criteria are completed.\textsuperscript{202}

---

**Tratamiento del paciente especial con esquizofrenia**

Las poblaciones de pacientes especiales con esquizofrenia han recibido poca atención. Estas poblaciones incluyen a los adolescentes, los viejos, los abusadores de sustancias y a los pacientes que se consideran resistentes al tratamiento. El interés en estas poblaciones ha sido de una rapidez creciente especialmente en relación con el tratamiento con antipsicóticos de segunda generación. Este artículo describe el tratamiento de las poblaciones de pacientes especiales y resume la investigación que se ha realizado en este campo.

**Traitement des populations particulières de patients atteints de schizophrénie**

Les populations particulières de patients présentant une schizophrénie ont jusqu’ici reçu peu d’attention. Ces populations comprennent les adolescents, les patients âgés, les toxicomanes et les patients qui sont considérés comme résistants au traitement. L’intérêt que l’on porte à ces populations est en pleine expansion, en particulier pour ce qui est de leur traitement par les antipsychotiques de deuxième génération. Cet article décrit le traitement de populations particulières de patients et fait le point sur la recherche dans ce domaine.
REFERENCES

1. Lantos PL. The neuropathology of schizophrenia. Progress and interpretation. J Neurol Neurosurg Psychiatry. 2001;70:421.

2. Baron M. Genetics of schizophrenia and the new millennium: progress and pitfalls. Am J Hum Genet. 2001;68:299-312.

3. Buckley PE, Buchanan RW, Tammenga CA, Shultz SC. Schizophrenia research: a progress report, summarizing proceedings of the 1999 International Congress on Schizophrenia Research. Schizophr Bull. 2000;26:411-419.

4. Beratis S, Gabriel J, Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr Bull. 1999;25:207-296.

5. Hafner H, Riecher-Rossler A, Maurer K, Fatkenheuer B, Loiffler W. First onset and early symptomatology of schizophrenia: a chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Neurol Sci. 1992;242:109-118.

6. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry. 1984;41:157-161.

7. Werry JS. Child and adolescent (early onset) schizophrenia: a review in light of DSM-III-R. J Autism Dev Disord. 1992;22:601-624.

8. Perry R, Williams S, Chellam JM, Charlton MJ. Childhood and adolescent schizophrenia, bipolar, and schizoaffective disorders: a clinical and outcome study. J Am Acad Child Adolesc Psychiatry. 1991;30:457-465.

9. Green M, Parducci A, Giallourgi M, Hardes JD, Fantini M. Schizophrenia with childhood onset: a phenomenological study of 38 cases. J Am Acad Child Adolesc Psychiatry. 1992;31:968-976.

10. Watkins JM, Asarnow RF, Tanguay PE. Symptom development in childhood-onset schizophrenia. J Child Psychol Psychiatry. 1988;29:865-878.

11. Asarnow JR, Ben-Meir S. Children with schizophrenia spectrum and depressive disorders: a comparative study of premorbid adjustment, onset pattern and severity of impairment. J Child Psychol Psychiatry. 1989;30:477-488.

12. Findling RL, Grochew SJ, Lopez I, Schulz SC. Antipsychotic medications in children and adolescents. J Clin Psychol. 1996;52(suppl 9):19-23.

13. Pool D, Bloom W, Mileke DH, Roniger JJ, Gailant DM. A controlled evaluation of loxapine in 75 adolescent schizophrenic patients. Can Ther Res Clin Exp. 1976;19:99-104.

14. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM. Clinical comparison of thioridazine and thiothixene in schizophrenic adolescent patients. Am J Psychiatry. 1984;141:440-442.

15. Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull. 1992;28:138-186.

16. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:538-663.

17. Remschmidt H, Schulz E, Martin M. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Clin Psychiatry. 1992;53:241-253.

18. Mozes T, Toren P, Chernauan N, et al. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:65-70.

19. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: an open label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry. 1998;37:15-16.

20. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioral disturbances of Prader-Willi syndrome Acta Psychiatr Scand. 2000;102:461-465.

21. Schreier HA. Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol. 1998;8:49-59.

22. Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry. 1999;38:960-965.

23. Kevely GD. Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry. 1999;38:1327-1328.

24. Hanna GL, Fluent TE, Fischer DJ. Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol. 1999;9:277-283.

25. Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol. 2000;10:18-26.

26. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509-516.

27. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in children with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry. 1997;36:604-607.

28. Marder SR, Meiback RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.

29. Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry. 1999;60:771-775.

30. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: Haloperidol-induced hepatocytotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry. 1997;36:701-705.

31. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics over 6 months. J Child Adolesc Psychopharmacol. 2000;10:779-780.

32. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2000;10:259-268.

33. Lavalaye J, Linszen DH, Boooi J, Reneman L, Gersons BP, van Royen EA. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res. 1999;92:34-44.

34. Zuddas A, Di Martino A, Muglia P, Gianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol. 1999;19:111-123.

35. Beasley CM, Tolleson G, Tran P, et al. Olanzapine versus placebo and haloperidol; acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.

36. Wudarsky M, Nicolson R, Hamberger SD, et al. Elevated prolactin in children and adolescents treated with risperidone and conventional antipsychotics over 6 months. J Child Adolesc Psychopharmacol. 1999;9:239-245.

37. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:37-44.

38. Wadsworth M, Nicolson R, Hamberger SD, et al. Elevated prolactin in children and adolescents treated with risperidone and conventional antipsychotics. J Child Adolesc Psychopharmacol. 1999;9:239-245.

39. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in children with pervasive developmental disorders. Acta Psychiatr Scand. 2000;102:461-465.

40. Thorpe L. The treatment of psychotic disorders in late life. Can J Psychiatry. 1997;42(suppl 1):195-275.

41. The epidemiology of mental disorders: results from the Epidemiologic Catchment Area Study (ECA). Psychopharmacol Bull. 1982;18:222-225.

42. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989;146:577-587.

43. Jeste DV, Eastham JM, Lacro JP, Gierz M, Field MG, Harris MJ. Management of late-life psychosis. J Clin Psychiatry. 1996;57:39-45.

44. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc. 1996;44:296-299.

45. Cummings JL, Miller B, Hill MA, Nesheks R. Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol. 1987;44:389-393.

46. Ray WA, Federspiel CF, Schaafner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health. 1980;70:485-491.

47. Federal Drug Administration. Omnibus Budget Reconciliation Act Guidelines of 1987. 54 Federal Register. 1989;5316-5336.
65. Jeste DV, Caliguri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52:756-765.

66. Madhusoodanan S, Brenner A, Alcantra A. Quetiapine in elderly patients with psychotic disorders. J Clin Ther. 2000;55:1753-1754.

67. Dewey RB, O’Suilleabhain PB. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology. 1998;50:1183-1184.

68. Weber JW, Minagar A, Shulman LM. Quetiapine for L-dopa-induced dyskinesias. Neurology. 1998;52:756-765.

69. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55(suppl 8);117-121.

70. Hauser WA. Seizure disorders: the changes with age. Epilepsia. 1992;33(suppl 4):S6-S14.

71. Chan YC, Pariser SF, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy. 1999;19:811-822.

73. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol. 2000;13:28-32.

80. Conley RR, Conley DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance. Schizophr Res. 1998;33:177-181.

81. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic in substance-abusing patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry. 1994;151:385-389.

82. Zisook S, Heaton R, Moranville J, Kuck J, Jernigan T, Braff D. Past substance abuse and schizophrenia: effect on symptoms but not on neurocognitive functions. J Clin Psychiatry. 1995;1:26-30.

83. Buckely P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry. 1994;151:385-389.

84. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40:101-104.

85. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55(suppl 8);117-121.

86. Dixon L, Bledizt E, Myers P, Conley R, Medoff D, Lehman AF. Comparison of DSM-III-R diagnoses and a brief interview for substance abuse among state hospital patients. Hosp Community Psychiatry. 1993;44:748-752.

87. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16:31-56.

88. Alterman AI, Ayre FR, Willford WO. Diagnostic validation of conjoint schizophrenia and alcoholism. J Clin Psychiatry. 1984;45:300-303.

89. Bowens MB, Mazure CM, Nelson JC, Jatlow P. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 1990;16:81-86.

90. Carpenter MD, Mulligan JC, Bader IA, Meiner AE. Multiple admissions to an urban psychiatric center: a comparative study. Hosp Community Psychiatry. 1985;36:1305-1308.

91. Gupta S, Hendricks S, Kenkel AM, Bhatia SC, Haffke EF. Relapse in schizophrenia: is there a relationship to substance abuse? Schizophr Res. 1996;20:153-156.

92. Haywood TW, Kravit HM, Grossman LS, Cavanaugh JS, Davis JM, Lewis DA. Predicting the “revolving door” phenomenon among patients with schizophrenia, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152:856-861.

93. Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifyable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry. 1995;152:1749-1756.

94. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1027 patients. Psychopharmacol Bull. 1997;33:177-181.

95. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance. Schizophr Res. 1998;33:95-101.

96. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis. 1989;177:408-414.

97. Sevy S, Kay SR, Opler LA, et al. Significance of cocaine history in schizophrenia. J Nerv Ment Dis. 1990;178:642-648.

98. Brady K, Anton R, Ballenger JC, et al. Cocaine abuse among schizophrenic patients. Am J Psychiatry. 1990;147:1164-1167.

99. Cleghorn JM, Kaplan RD, Szechtm B, et al. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive functions. J Clin Psychiatry. 1994;51:26-30.

100. Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry. 1994;151:385-389.

101. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1993;150:552-553.

102. Love RC, Kelly DL, Bartko JJ. A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics. Schizophr Res. 1998;36:345-352.

103. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337:809-815.

104. Weiden P, Aquila R, Standle J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57(suppl 11):53-60.

105. Gale E, Hinch K, Kent D, Conley R. Olanzapine response in treatment resistant schizophrenics with substance abuse. Schizophr Res. 1995;15:150-151.

106. Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine [letter]. JAMA. 1994;318:224-230.

107. Zisook S, Heaton R, Moranville J, Kuck J, Jernigan T, Braff D. Past substance abuse and clinical course of schizophrenia. Am J Psychiatry. 1992;149:552-553.

108. Love RC, Kelly DL, Conley RR, Bartko JJ. A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics. Schizophr Res. 1998;36:345-352.

109. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337:809-815.

110. Weiden P, Aquila R, Standle J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57(suppl 11):53-60.

111. Gale E, Hinch K, Kent D, Conley R. Olanzapine response in treatment resistant schizophrenics with substance abuse. Schizophr Res. 1995;15:150-151.

112. Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine [letter]. JAMA. 1994;149:224-230.
114. Misra LK, Kofoed L, Fuller W. Treatment of inhalant abuse with risperidone. J Clin Psychiatry. 1999;60:620.

115. Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N. Methamphetamine-associated obsessive symptoms and effective risperidone treatment: a case report. J Clin Psychiatry. 1999;60:337-338.

116. Roy A, Roy M, Smelson DA. Risperidone, ERG and cocaine craving. Am J Addict. 1998;7:90.

117. Smelson DA, Roy A, Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry. 1997;42:994.

118. Misra L, Kofoed L. Risperidone treatment of metamphetamine psychosis. Am J Psychiatry. 1997;154:1170.

119. Soylek M, Wegner U, Moeller HJ. Risperidone in treatment-refractory chronic alcohol hallucinosis. Psychopharmacology. 1997;132:1315-1317.

120. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol. 2000;20:305-310.

121. Berk M, Btorch S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized trial. J Clin Psychopharmacol. 1997;17:260-264.

122. Penk WE, Flannery RB, Irvin E, Geller J, Fisher W, Hanson MA. Characteristics of substance-abusing persons with schizophrenia: the paradox of the dually diagnosed. J Addict Dis. 2000;19:23-39.

123. Jnain Y, Goetz A, Goujon JM. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health—Psychopharmacology Research Branch Collaborative Study Group. Arch Gen Psychiatry. 1968;19:182.

124. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs. 1977;14:260-282.

125. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Arch Gen Psychiatry. 1990;16:551-561.

126. McKinney PW, Harn TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull. 1988;14:515-542.

127. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 1988;45:789-796.

128. Holden JM, Hilt TM, Keshner A, Fink M. Thioridazine and chlorpromazine in treatment-resistant schizophrenia. J Addict Dis. 1998;17:343-437.

129. Small JG, Kellams JJ, Milstein V, Moore J. A placebo-controlled study of risperidone and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1996;53:754-758.

130. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull. 1995;21:567-577.

131. Dzenger SJ, Kulhanet F, eds. Treatment Resistance in Schizophrenia. Braun worried. Germany: Vieweg Verlag; 1988.

132. Stern RG, Kahn RS, Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 1993;16:313-332.

133. Bilder RM, Wu H, Chakos MH, et al. Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry. 1994;55(suppl B):8-53.

134. Ota P, Masghio H, Fidler D, et al. Treatment resistant chronic psychopathology and CT scans in schizophrenia. Acta Psychiatric Scand. 1978;75:415-427.

135. Van Kammen DP, Schooler N. Are biochemical markers for treatment-resistant schizophrenia state dependent or traits? Clin Neuropharmacol. 1990;13(suppl 1):516-528.

136. Pickard D, Breier A, Kelsoe J. Plasma homovanillic acid as an index of cerebral dopaminergic activity: studies in schizophrenia patients. Ann N Y Acad Sci. 1988;537:339-346.

137. Rodriguez VM, Catalan ML, Garcia-Noblejas JA, Cuesta P. Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenic. Psychiatry Res. 1998;77:21-28.

138. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151:20-26.

139. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenic. Schizophrenia Bull. 1997;23:663-674.

140. Bak TH, Bauer M, Schaub RT, Hellweg R, Reischies FM. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry. 1995;56:418-422.

141. Wrisching DA, Marshall BD, Green MF, Mintz J, Marder SR, Wrisching WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1997;154:1374-1378.

142. Wahlbeck K, Cheine M, Tuusku K, Ahokas A, Joffe G, Rimoin R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:911-922.

143. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998;155:499-504.

144. Flynn SW, MacEwan GW, Altman S, et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 1998;31:25-29.

145. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999;45:403-411.

146. Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Resistant Schizophrenia. J Clin Psychiatry. 1997;58:479-483.

147. Dosenbach MRK, Beuzen JN, Avnon M, et al. The effect of olanzapine in treatment-resistant schizophrenia: a double-blind, placebo-controlled study. The Olanzapine Study Group. Am J Psychiatry. 1999;156:1374-1379.

148. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1999;156:914-920.

149. Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 1999;46:73-77.
166. Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol. 1999;19:62-66.
167. Reznik I, Benatov R, Sirota F. Seroquel in a resistant schizophrenic with negative and positive symptoms [in Hebrew]. Harefuah. 1996;130:675-677,727.
168. Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17:366-378.
169. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects ofquetiapine ("seroquel") and haloperidol in schizophrenic patients with a history of a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000;15:121-131.
170. Grove GA, Crayton JW, Klass DB, Evans H, Strizich M. Lithium in chronic schizophrenia. Am J Psychiatry. 1979;136(4A):454-455.
171. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull. 1995;21:607-619.
172. Schulz SC, Thompson PA, Jacobs M, et al. Lithium augmentation to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry. 1999;60:366-372.
173. Martin JC, Palenciano G, Perez R. The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia. J Clin Psychiatry. 2000;61:948.
174. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. JAMA. 1974;230:1283-1287.
175. Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose-dependent. J Psychopharmacol. 1987;7:89-91.
176. Post RM. Non-lithium treatment for bipolar disorder. J Clin Psychiatry. 1990;51(suppl):9-16.
177. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992;149:108-111.
178. Kahan EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine—a complicating factor in combined medication for schizophrenia. J Clin Psychiatry. 1990;51:54-57.
179. Eustis SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry. 1999;56:950.
180. Thanayan P. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2000,CD000076.
181. Kuchik M, Spivak B, Mester R, et al. Combined electroconvulsive-clozapine therapy. Clin Neuropharmacol. 2000;23:14-16.
182. Kales HC, Donquardo JR, Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:547-956.
183. Dursun SM, McIntosh D, Millekien H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry. 1999;56:950.
184. Benatov R, Sirota F. Meegeid S. Neuroleptic-resistant schizophrenia treated with clozapine and ETC. Convulsive Ther. 1996;12:117-121.
185. Remington GJ, Addington D, Collins EJ, et al. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Can J Psychiatry. 1996;41:161-166.
186. Keks NA, Althorn K, Hope J, et al. Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Aust NZ J Psychiatry. 1999;33:896-901.
187. Stahl SM. Antipsychotic polypharmacy. Part 1. Therapeutic option or dirty little secret? J Clin Psychiatry. 1999;60:425-426.
188. Adesanya A, Pantels C. Adjunctive risperidone treatment in patients with "clozapine-resistant schizophrenia." Aust NZ J Psychiatry. 2000;34:333-334.
189. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenia. J Clin Psychiatry. 1996;57:395-397.
190. Raskin S, Katz G, Zislin Z, Knobler HY, Durst R. Clozapine and risperidone: combination/ augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand. 2000;101:334-336.
191. Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand. 1999;99:395-396.
192. McCarthy RH, Terkelson KG. Risperidone augmentation of clozapine. Pharmacopsychiatry. 1995;28:61-63.
193. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Acta Psychiatr Scand. 1998;10:113-115.
194. Lemer V, Chudakov B, Kralevs S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol. 2000;23:2-284-286.
195. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry. 1996;8:193-197.
196. Rankin S, Rust D, Katz G, Zislan J. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol. 2000;20:500-503.
197. Shiloah R, Zemishlany Z, Alzenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573.
198. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry. 1997;42:522-523.
199. Wolowitz OM, Turetsky N, Reus VI, Haregraves WA. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull. 1992;28:291-295.
200. Hanlon TE, Ota KY, Kurland AA. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Disord Nerv System. 1970;31:171-177.
201. Pato CN, Wolowitz OM, Rapaport M, Schulz SC, Pickar D. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull. 1989;25:263-266.
202. Wahlbeck K, Cheine MV, Gilbody S, Ahonen J. Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials. Schizophr Res. 2000;41:341-347.